Jie Zhang

Company: Novartis

Job title: Vice President & Head of Cell & Gene Global Value & Access

Seminars:

Launching Therapies into a Volatile Market & Strategies to Overcome Compounding Challenges for Successful Introduction & Market Adaptation for New Products 2:15 pm

Recognizing the increasing challenges arising from multiple cell and gene therapies competing for budgets Assessing the cumulative budget impact of these therapies collectively rather than individually Navigating access and pricing challenges in cell therapy beyond haematology indications to unlock new frontiers and explore opportunities for advancement and patient benefitRead more

day: Conference Day Two

Panel Discussion: Reviewing Global Market Access & Challenges to Streamline Ongoing Strategies & Improve Patient Access 9:00 am

What are the key challenges that are currently hindering effective pricing and reimbursement globally What challenges have we overcome during the commercialization of currently approved cell and gene therapies? What challenges will be a priority to tackle in the next 5 years? What is the global state of cell and gene therapies?Read more

day: Conference Day One

Exploring Strategic Insights into the Commercial Strategy Implications of the Inflation Reduction Act for Cell & Gene Therapy Administration to Ensure Strategic Advantages for Future Development Initiatives 9:01 am

Cell and gene therapies have some of the highest manufacturer prices in the US and so are an obvious target for negotiation. Therefore, the CMS is proceeding with implementing the provisions of the 2022 IRA. This legislation is expected to set upper limits on the negotiated price between manufacturers and US government-funded drug plans for…Read more

day: Pre-Conference Workshop Day